Nilotinib: Difference between revisions
From Proteopedia
Jump to navigationJump to search
David Canner (talk | contribs) No edit summary |
David Canner (talk | contribs) No edit summary |
||
| Line 1: | Line 1: | ||
<applet load="" size="480" color="" frame="true" spin="on" Scene ="" align="right" caption="Nilotinib, also known as Tasigna ([[3cs9]])"/> | <applet load="" size="480" color="" frame="true" spin="on" Scene ="" align="right" caption="Nilotinib, also known as Tasigna ([[3cs9]])"/> | ||
===Better Known as: Tasigna=== | ===Better Known as: Tasigna=== | ||
* Marketed By: | * Marketed By: Novartis | ||
* Major Indication: Chronic Myelogenous [[Cancer|Leukemia]] | * Major Indication: Chronic Myelogenous [[Cancer|Leukemia]] | ||
* Drug Class: Receptor Tyrosine Kinase (Especially BCR-Abl) Inhibitor | * Drug Class: Receptor Tyrosine Kinase (Especially BCR-Abl) Inhibitor | ||
* Date of FDA Approval (Expiration): | * Date of FDA Approval (Expiration): 2007 (2023) | ||
* | * Expected Sales in Combination with [[Imatinib]]: $3.5 Billion | ||
* Importance: | * Importance: | ||
* See [[Pharmaceutical Drugs]] for more information about other drugs and disorders | * See [[Pharmaceutical Drugs]] for more information about other drugs and disorders | ||
